← Find more feeds

chugai-pharm.co.jp

Chugai Pharmaceutical: News Releases

Get the latest updates from Chugai Pharmaceutical: News Releases directly as they happen.

Follow now 174 followers

Latest posts

Last updated 20 days ago

Roche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)

20 days ago

Read full

Roche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)

21 days ago

Read full

Launch of Joint Research Using Real-World Data and Generative AI (LLM) to Improve the Accuracy and Efficiency of Identifying Candidate Patients for Clinical Trials

22 days ago

Read full

Anti-CD20 Monoclonal Antibody Rituxan® Approved for Adult-onset Frequently Relapsing or Steroid-dependent Nephrotic Syndrome

about 1 month ago

Read full

Avastin Receives Approval for Additional Indication as the World’s First Treatment for Neurofibromatosis Type 2

about 1 month ago

Read full

Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy

about 1 month ago

Read full

Tecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancer

about 1 month ago

Read full

Chugai Receives “The Imperial Invention Prize,” the Highest Honor of the FY2026 National Commendation for Invention — Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research —

about 2 months ago

Read full

Organizational and Personnel Changes

about 2 months ago

Read full

Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors

2 months ago

Read full

Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients

2 months ago

Read full

Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome

2 months ago

Read full

Or log in

Everything you care about in one place

Chugai Pharmaceutical: News Releases

Latest posts

Roche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)

Roche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)

Launch of Joint Research Using Real-World Data and Generative AI (LLM) to Improve the Accuracy and Efficiency of Identifying Candidate Patients for Clinical Trials

Anti-CD20 Monoclonal Antibody Rituxan® Approved for Adult-onset Frequently Relapsing or Steroid-dependent Nephrotic Syndrome

Avastin Receives Approval for Additional Indication as the World’s First Treatment for Neurofibromatosis Type 2

Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy

Tecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancer

Chugai Receives “The Imperial Invention Prize,” the Highest Honor of the FY2026 National Commendation for Invention — Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research —

Organizational and Personnel Changes

Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors

Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients

Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome

Try Feeder for free